These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21176109)

  • 1. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension.
    Guimaraes DA; Rizzi E; Ceron CS; Oliveira AM; Oliveira DM; Castro MM; Tirapelli CR; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2011 May; 108(5):318-25. PubMed ID: 21176109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.
    Castro MM; Rizzi E; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
    Matrix Biol; 2010 Apr; 29(3):194-201. PubMed ID: 19969080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.
    Martinez ML; Castro MM; Rizzi E; Fernandes K; Demacq C; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Sep; 591(1-3):224-30. PubMed ID: 18634778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats.
    Castro MM; Rizzi E; Figueiredo-Lopes L; Fernandes K; Bendhack LM; Pitol DL; Gerlach RF; Tanus-Santos JE
    Atherosclerosis; 2008 Jun; 198(2):320-31. PubMed ID: 18054360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine.
    Jacob-Ferreira AL; Palei AC; Cau SB; Moreno H; Martinez ML; Izidoro-Toledo TC; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2010 Feb; 627(1-3):216-22. PubMed ID: 19879865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course involvement of matrix metalloproteinases in the vascular alterations of renovascular hypertension.
    Ceron CS; Rizzi E; Guimaraes DA; Martins-Oliveira A; Cau SB; Ramos J; Gerlach RF; Tanus-Santos JE
    Matrix Biol; 2012 May; 31(4):261-70. PubMed ID: 22342460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension.
    Castro MM; Rizzi E; Rodrigues GJ; Ceron CS; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2009 May; 46(9):1298-307. PubMed ID: 19248829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes.
    Rizzi E; Castro MM; Ceron CS; Neto-Neves EM; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
    Int J Cardiol; 2013 Apr; 165(1):165-73. PubMed ID: 21917342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension.
    Rizzi E; Castro MM; Fernandes K; Barbosa F; Arisi GM; Garcia-Cairasco N; Bendhack LM; Tanus-Santos JE; Gerlach RF
    Arch Toxicol; 2009 May; 83(5):439-49. PubMed ID: 18836702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-α inhibition decreases MMP-2 activity, reactive oxygen species formation and improves hypertensive vascular hypertrophy independent of its effects on blood pressure.
    Mattos BR; Bonacio GF; Vitorino TR; Garcia VT; Amaral JH; Dellalibera-Joviliano R; Franca SC; Tanus-Santos JE; Rizzi E
    Biochem Pharmacol; 2020 Oct; 180():114121. PubMed ID: 32592722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling.
    Martins-Oliveira A; Castro MM; Oliveira DM; Rizzi E; Ceron CS; Guimaraes D; Reis RI; Costa-Neto CM; Casarini DE; Ribeiro AA; Gerlach RF; Tanus-Santos JE
    Int J Cardiol; 2013 Aug; 167(4):1199-205. PubMed ID: 22483258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability.
    Castro MM; Rizzi E; Ceron CS; Guimaraes DA; Rodrigues GJ; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Nitric Oxide; 2012 Mar; 26(3):162-8. PubMed ID: 22327038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats.
    Martinez ML; Rizzi E; Castro MM; Fernandes K; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Dec; 599(1-3):110-6. PubMed ID: 18930722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II increases tissue-specific inhibitor of metalloproteinase-2 expression in rat aortic smooth muscle cells in vivo: evidence of a pressure-independent effect.
    Castoldi G; di Gioia CR; Travaglini C; Busca G; Redaelli S; Bombardi C; Stella A
    Clin Exp Pharmacol Physiol; 2007 Mar; 34(3):205-9. PubMed ID: 17250640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal changes in cardiac matrix metalloproteinase activity, oxidative stress, and TGF-β in renovascular hypertension-induced cardiac hypertrophy.
    Rizzi E; Ceron CS; Guimaraes DA; Prado CM; Rossi MA; Gerlach RF; Tanus-Santos JE
    Exp Mol Pathol; 2013 Feb; 94(1):1-9. PubMed ID: 23073243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.
    Marçal DM; Rizzi E; Martins-Oliveira A; Ceron CS; Guimaraes DA; Gerlach RF; Tanus-Santos JE
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):35-44. PubMed ID: 21058008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metalloproteinase Inhibition Protects against Reductions in Circulating Adrenomedullin during Lead-induced Acute Hypertension.
    Nascimento RA; Mendes G; Possomato-Vieira JS; Gonçalves-Rizzi VH; Kushima H; Delella FK; Dias-Junior CA
    Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):508-15. PubMed ID: 25308714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolidine dithiocarbamate down-regulates vascular matrix metalloproteinases and ameliorates vascular dysfunction and remodelling in renovascular hypertension.
    Cau SB; Guimaraes DA; Rizzi E; Ceron CS; Souza LL; Tirapelli CR; Gerlach RF; Tanus-Santos JE
    Br J Pharmacol; 2011 Sep; 164(2):372-81. PubMed ID: 21434884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR.
    Antonio RC; Ceron CS; Rizzi E; Coelho EB; Tanus-Santos JE; Gerlach RF
    Mol Cell Biochem; 2014 Jan; 386(1-2):99-105. PubMed ID: 24114660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension.
    Castro MM; Tanus-Santos JE; Gerlach RF
    Pharmacol Res; 2011 Dec; 64(6):567-72. PubMed ID: 21514386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.